Longer follow-up presented at the 2026 ESMO Congress showed that four already-approved treatments for early breast cancer, kidney cancer, colorectal cancer and stomach and esophageal cancer kept helping patients years later.
Commentary|Articles|January 22, 2026
Key Patient Takeaways From the 2026 ASCO GI Cancers Symposium
Author(s)Ryan Scott
Fact checked by: Spencer Feldman
Experts highlight key themes from the ASCO GI Cancers Symposium, including the growing role of AI and an increased emphasis on patient-centered decision-making.
Advertisement
Advertisement
During the
Related to this article
Five phase 3 trials presented at ESMO 2026 showed new options in small cell lung, bladder, prostate, KRAS G12C lung and stomach cancers. Here is what each found and what it means for patients.
The Whipple procedure is the main operation for cancer in the head of the pancreas. Here is what is removed, what the hospital stay is like, the complications to know about and how eating changes afterward.
Immunotherapy is a mainstay of lung cancer treatment, and its side effects are different from chemotherapy's. Here are five to know, what they feel like and how care teams treat them.
Brad Dugai and Russ Reed discuss symptom relief, skin-related side effects and challenges accessing Rasonque, a treatment for pancreatic cancer.
Patients with PD-L1-negative non-small cell lung cancer experienced longer progression-free survival with sac-TMT plus Keytruda compared with chemotherapy plus Keytruda in a phase 3 trial.
For National Hospice and Palliative Care Month, answers to common questions about how palliative care differs from hospice, who qualifies, what Medicare covers and how to find a program.
A nurse practitioner discusses how an app provides information on cancer treatments, potential side effects and preparing for medical appointments.
Advertisement
Advertisement